| Bioactivity | Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma[1]. |
| Target | CD80 |
| Name | Galiximab |
| CAS | 357613-77-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405-10. |